<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525512</url>
  </required_header>
  <id_info>
    <org_study_id>205.368</org_study_id>
    <secondary_id>2006-004610-41</secondary_id>
    <nct_id>NCT00525512</nct_id>
  </id_info>
  <brief_title>Tiotropium In Exercise</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Two-year Trial to Examine the Changes in Exercise Endurance and COPD Treated With Tiotropium Once Daily (EXACTT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effects on exercise duration of 96 weeks
      treatment with 18 mcg tiotropium (Spiriva HandiHaler) daily as compared to placebo, in
      patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90% Constant Work Rate (CWR) Treadmill Endurance Time at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>90% Constant Work Rate (CWR) Treadmill Endurance Time at 8 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90% Constant Work Rate (CWR) Treadmill Endurance Time at 16 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90% Constant Work Rate (CWR) Treadmill Endurance Time at 32 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 32 weeks</time_frame>
    <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90% Constant Work Rate (CWR) Treadmill Endurance Time at 48 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90% Constant Work Rate (CWR) Treadmill Endurance Time at 64 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 64 weeks</time_frame>
    <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90% Constant Work Rate (CWR) Treadmill Endurance Time at 80 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 80 weeks</time_frame>
    <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 8 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 16 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 32 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 32 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 48 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 64 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 64 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 80 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 80 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 8 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 16 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 32 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 32 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 48 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 64 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 64 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 80 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 80 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Vital Capacity (FVC) at 8 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Vital Capacity (FVC) at 16 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Vital Capacity (FVC) at 32 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 32 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Vital Capacity (FVC) at 48 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Vital Capacity (FVC) at 64 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 64 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Vital Capacity (FVC) at 80 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 80 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Forced Vital Capacity (FVC) at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Vital Capacity (FVC) at 8 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Vital Capacity (FVC) at 16 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Vital Capacity (FVC) at 32 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 32 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Vital Capacity (FVC) at 48 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Vital Capacity (FVC) at 64 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 64 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Vital Capacity (FVC) at 80 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 80 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Vital Capacity (FVC) at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg Scale of Dyspnea at Isotime After 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>Borg scale assessed degreee of discomfort on a scale from 0 (Nothing at all) to 10 (Maximal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg Scale of Peak Dyspnea After 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>Borg scale assessed degreee of discomfort on a scale from 0 (Nothing at all) to 10 (Maximal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg Scale of Peak Leg Discomfort After 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>Borg scale assessed degreee of discomfort on a scale from 0 (Nothing at all) to 10 (Maximal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Evaluation at 8 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Evaluation at 16 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Evaluation at 32 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 32 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Evaluation at 48 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Evaluation at 64 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 64 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Evaluation at 80 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 80 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Evaluation at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Evaluation at 8 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Evaluation at 16 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Evaluation at 32 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 32 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Evaluation at 48 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Evaluation at 64 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 64 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Evaluation at 80 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 80 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Evaluation at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire Total Score at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire Activity Component Score at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire Impact Component Score at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire Symptoms Component Score at 96 Weeks - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With COPD Exacerbation (Survival Analysis) - Double-Blind Phase</measure>
    <time_frame>baseline, 96 weeks</time_frame>
    <description>COPD exacerbation is a complex of symptoms related to COPD with a duration of three days or more requiring a change of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90% Constant Work Rate (CWR) Treadmill Endurance Time at 100 Weeks - Open-Label Phase</measure>
    <time_frame>baseline, 100 weeks</time_frame>
    <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 100 Weeks - Open-Label Phase</measure>
    <time_frame>baseline, 100 weeks</time_frame>
    <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Forced Vital Capacity (FVC) at 100 Weeks - Open-Label Phase</measure>
    <time_frame>baseline, 100 weeks</time_frame>
    <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire Total Score at 100 Weeks - Open-Label Phase</measure>
    <time_frame>baseline, 100 weeks</time_frame>
    <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire Activity Component Score at 100 Weeks - Open-Label Phase</measure>
    <time_frame>baseline, 100 weeks</time_frame>
    <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire Impact Component Score at 100 Weeks - Open-Label Phase</measure>
    <time_frame>baseline, 100 weeks</time_frame>
    <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire Symptoms Component Score at 100 Weeks - Open-Label Phase</measure>
    <time_frame>baseline, 100 weeks</time_frame>
    <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs and Physical Examination, Including Vital Status</measure>
    <time_frame>From first drug administration until 30 days after last drug administration</time_frame>
    <description>Clinical Relevant Abnormalities for Vital Signs and Physical examination, including vital status. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">519</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Exercise</condition>
  <arm_group>
    <arm_group_label>tiotropium 18mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral inhalation once daily of 18mcg tiotropium via handihaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral inhalation once daily of placebo matching tiotropium via handihaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium 18 mcg</intervention_name>
    <description>Oral inhalation once daily of 18mcg tiotropium via handihaler</description>
    <arm_group_label>tiotropium 18mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral inhalation of once-daily placebo matching tiotropium via handihaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. All patients must sign an informed consent

          2. Diagnosis of COPD with specific spirometric criteria (determined at study visits)

          3. Age &gt;= 40 years

          4. Medical Research Council Dyspnoea score &gt;= 2

          5. Current or ex-smoker with a &gt;= 10 pack-year smoking history

          6. Ability to exercise on treadmill

        Exclusion criteria

          1. Significant diseases other than COPD such as history of life-threatening pulmonary
             obstruction, thoracotomy with pulmonary resection, interstitial lung disease, CF,
             pulmonary thromboembolic disease, clinically evident bronchiectasis, active
             tuberculosis, or known moderate to severe renal impairment

          2. Clinical history of asthma

          3. Use of supplemental oxygen therapy

          4. Respiratory tract infection or COPD exacerbation in the 6 weeks prior to Visit 1 or
             during the washout period prior to Visit 3 (may randomize 6 weeks after recovery)

          5. Recent history (&lt;= 12 months) of myocardial infarction

          6. Unstable or life-threatening cardiac arrhythmia

          7. Malignancy treated with radiation therapy or chemotherapy in the last 5 years

          8. Pregnant or nursing women

          9. Known hypersensitivity to anticholinergic drugs or any component of the study
             medications

         10. Participation in pulmonary or cardiac rehab program within 13 weeks of Visit 1

         11. Estimated life expectancy &lt; 2 years

         12. Symptomatic prostatic hyperplasia or bladder neck obstruction

         13. Known narrow-angle glaucoma

         14. Any condition that is contraindicated for exercise

         15. Orthopaedic, muscular, neurological or cardiac disease that would interfere with
             regular participation in aerobic exercise or with exercise testing

         16. Body mass index &lt; 18 kg/m2 or &gt;35 kg/m2 list truncated for space
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.368.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vicente López</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.55003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.55004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre - RS</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.55002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.07008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg/Breisgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schmallenberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.35103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matosinhos</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.34005 Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.34002 Hospital de Cruces</name>
      <address>
        <city>Barakaldo (Bilbao)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.34001 Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.34003 Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.34004 Hospital Universitario Vírgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.88604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.88601 Chang Gung Memorial Hosp-Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnyepropyetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.368.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Poland</country>
  </removed_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2007</study_first_submitted>
  <study_first_submitted_qc>September 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <results_first_submitted>June 27, 2011</results_first_submitted>
  <results_first_submitted_qc>August 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2011</results_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients randomized to receive treatment with matching placebo</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium</title>
          <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
        </group>
        <group group_id="P3">
          <title>Placebo / Open Tiotropium</title>
          <description>Patients receive open label tiotropium following placebo</description>
        </group>
        <group group_id="P4">
          <title>Tiotropium / Open Tiotropium</title>
          <description>Patients receive open label tiotropium following tiotropium</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="259"/>
                <participants group_id="P2" count="260"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason (not specified)</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="164"/>
                <participants group_id="P4" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason (not specified)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients randomized to receive treatment with matching placebo</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium</title>
          <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="259"/>
            <count group_id="B2" value="260"/>
            <count group_id="B3" value="519"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="8.5"/>
                    <measurement group_id="B2" value="64.7" spread="8.2"/>
                    <measurement group_id="B3" value="64.6" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 55 to &lt;= 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian / Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black / African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian / Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>pack years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.04" spread="26.29"/>
                    <measurement group_id="B2" value="52.15" spread="28.95"/>
                    <measurement group_id="B3" value="51.6" spread="27.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of COPD (Chronic Obstructive Pulmonary Disease)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.80" spread="6.99"/>
                    <measurement group_id="B2" value="8.70" spread="6.27"/>
                    <measurement group_id="B3" value="8.75" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.6" spread="8.5"/>
                    <measurement group_id="B2" value="169.7" spread="9.2"/>
                    <measurement group_id="B3" value="169.7" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.4" spread="15.0"/>
                    <measurement group_id="B2" value="75.4" spread="16.0"/>
                    <measurement group_id="B3" value="76.4" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (Body Mass Index)</title>
          <units>kilograms / square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="4.23"/>
                    <measurement group_id="B2" value="26.0" spread="4.38"/>
                    <measurement group_id="B3" value="26.4" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - no interference with study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - possible interference with study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LABA (Long Acting Beta Agonist) use at randomization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ICS (Inhaled Cortico Steroid) use at randomization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LABA / ICS use at randomization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anticholinergic use at screening</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 96 Weeks - Double-Blind Phase</title>
        <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <population>Full Analysis Set (FAS) includes all treated participants with a baseline and any post-dosing exercise duration data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 96 Weeks - Double-Blind Phase</title>
          <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
          <population>Full Analysis Set (FAS) includes all treated participants with a baseline and any post-dosing exercise duration data</population>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297.1" lower_limit="265.0" upper_limit="333.0"/>
                    <measurement group_id="O2" value="336.6" lower_limit="302.5" upper_limit="374.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1062</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 8 Weeks - Double-Blind Phase</title>
        <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 8 Weeks - Double-Blind Phase</title>
          <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.9" lower_limit="284.7" upper_limit="326.5"/>
                    <measurement group_id="O2" value="343.0" lower_limit="321.2" upper_limit="366.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 16 Weeks - Double-Blind Phase</title>
        <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
        <time_frame>baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 16 Weeks - Double-Blind Phase</title>
          <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308.6" lower_limit="286.2" upper_limit="332.8"/>
                    <measurement group_id="O2" value="338.6" lower_limit="315.2" upper_limit="363.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0597</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 32 Weeks - Double-Blind Phase</title>
        <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
        <time_frame>baseline, 32 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 32 Weeks - Double-Blind Phase</title>
          <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.8" lower_limit="286.3" upper_limit="339.5"/>
                    <measurement group_id="O2" value="358.7" lower_limit="330.9" upper_limit="388.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0131</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 48 Weeks - Double-Blind Phase</title>
        <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 48 Weeks - Double-Blind Phase</title>
          <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309.8" lower_limit="284.0" upper_limit="337.9"/>
                    <measurement group_id="O2" value="365.7" lower_limit="336.8" upper_limit="397.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean ratio</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 64 Weeks - Double-Blind Phase</title>
        <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
        <time_frame>baseline, 64 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 64 Weeks - Double-Blind Phase</title>
          <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313.4" lower_limit="284.7" upper_limit="344.9"/>
                    <measurement group_id="O2" value="349.0" lower_limit="318.7" upper_limit="382.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0945</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 80 Weeks - Double-Blind Phase</title>
        <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
        <time_frame>baseline, 80 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 80 Weeks - Double-Blind Phase</title>
          <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.8" lower_limit="273.5" upper_limit="335.2"/>
                    <measurement group_id="O2" value="340.1" lower_limit="309.0" upper_limit="374.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0899</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 8 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 8 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.082" spread="0.017"/>
                    <measurement group_id="O2" value="1.198" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.116</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.160</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 16 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 16 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.082" spread="0.018"/>
                    <measurement group_id="O2" value="1.164" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.128</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 32 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 32 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 32 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.090" spread="0.019"/>
                    <measurement group_id="O2" value="1.179" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.089</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.041</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 48 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 48 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.066" spread="0.019"/>
                    <measurement group_id="O2" value="1.172" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.105</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.058</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 64 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 64 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 64 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.066" spread="0.020"/>
                    <measurement group_id="O2" value="1.157" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.090</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.141</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 80 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 80 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 80 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.039" spread="0.019"/>
                    <measurement group_id="O2" value="1.134" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.094</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 96 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Expiratory Volume in 1 Second (FEV1) at 96 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.050" spread="0.021"/>
                    <measurement group_id="O2" value="1.125" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0059</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.075</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.128</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 8 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 8 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.126" spread="0.017"/>
                    <measurement group_id="O2" value="1.280" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.154</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.110</ci_lower_limit>
            <ci_upper_limit>0.198</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 16 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 16 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.092" spread="0.017"/>
                    <measurement group_id="O2" value="1.254" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.162</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.117</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 32 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 32 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 32 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.113" spread="0.018"/>
                    <measurement group_id="O2" value="1.259" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.145</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.099</ci_lower_limit>
            <ci_upper_limit>0.192</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 48 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 48 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.105" spread="0.019"/>
                    <measurement group_id="O2" value="1.232" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.127</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 64 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 64 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 64 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.097" spread="0.020"/>
                    <measurement group_id="O2" value="1.230" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.134</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 80 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 80 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 80 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.079" spread="0.020"/>
                    <measurement group_id="O2" value="1.228" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.097</ci_lower_limit>
            <ci_upper_limit>0.202</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 96 Weeks - Double-Blind Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 96 Weeks - Double-Blind Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.072" spread="0.021"/>
                    <measurement group_id="O2" value="1.202" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.130</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.183</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Vital Capacity (FVC) at 8 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Vital Capacity (FVC) at 8 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.432" spread="0.035"/>
                    <measurement group_id="O2" value="2.649" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.217</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.127</ci_lower_limit>
            <ci_upper_limit>0.307</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Vital Capacity (FVC) at 16 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Vital Capacity (FVC) at 16 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.407" spread="0.038"/>
                    <measurement group_id="O2" value="2.564" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.157</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.058</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Vital Capacity (FVC) at 32 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 32 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Vital Capacity (FVC) at 32 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.425" spread="0.040"/>
                    <measurement group_id="O2" value="2.607" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.182</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>0.286</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Vital Capacity (FVC) at 48 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Vital Capacity (FVC) at 48 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.406" spread="0.041"/>
                    <measurement group_id="O2" value="2.640" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.234</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.130</ci_lower_limit>
            <ci_upper_limit>0.339</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Vital Capacity (FVC) at 64 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 64 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Vital Capacity (FVC) at 64 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.423" spread="0.046"/>
                    <measurement group_id="O2" value="2.584" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.161</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.281</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Vital Capacity (FVC) at 80 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 80 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Vital Capacity (FVC) at 80 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.343" spread="0.042"/>
                    <measurement group_id="O2" value="2.555" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.212</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.322</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Forced Vital Capacity (FVC) at 96 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Forced Vital Capacity (FVC) at 96 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.368" spread="0.044"/>
                    <measurement group_id="O2" value="2.609" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.241</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.128</ci_lower_limit>
            <ci_upper_limit>0.355</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Vital Capacity (FVC) at 8 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Vital Capacity (FVC) at 8 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.529" spread="0.038"/>
                    <measurement group_id="O2" value="2.806" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.277</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.179</ci_lower_limit>
            <ci_upper_limit>0.375</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Vital Capacity (FVC) at 16 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Vital Capacity (FVC) at 16 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.442" spread="0.039"/>
                    <measurement group_id="O2" value="2.767" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.325</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.226</ci_lower_limit>
            <ci_upper_limit>0.425</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Vital Capacity (FVC) at 32 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 32 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Vital Capacity (FVC) at 32 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.462" spread="0.042"/>
                    <measurement group_id="O2" value="2.816" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.353</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.245</ci_lower_limit>
            <ci_upper_limit>0.461</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Vital Capacity (FVC) at 48 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Vital Capacity (FVC) at 48 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.499" spread="0.041"/>
                    <measurement group_id="O2" value="2.758" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.259</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.154</ci_lower_limit>
            <ci_upper_limit>0.365</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Vital Capacity (FVC) at 64 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 64 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Vital Capacity (FVC) at 64 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.466" spread="0.041"/>
                    <measurement group_id="O2" value="2.767" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.300</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.194</ci_lower_limit>
            <ci_upper_limit>0.406</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Vital Capacity (FVC) at 80 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 80 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Vital Capacity (FVC) at 80 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.479" spread="0.043"/>
                    <measurement group_id="O2" value="2.733" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.254</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.144</ci_lower_limit>
            <ci_upper_limit>0.364</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Vital Capacity (FVC) at 96 Weeks - Double-Blind Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Vital Capacity (FVC) at 96 Weeks - Double-Blind Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.420" spread="0.048"/>
                    <measurement group_id="O2" value="2.753" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.333</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.209</ci_lower_limit>
            <ci_upper_limit>0.456</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg Scale of Dyspnea at Isotime After 96 Weeks - Double-Blind Phase</title>
        <description>Borg scale assessed degreee of discomfort on a scale from 0 (Nothing at all) to 10 (Maximal)</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Borg Scale of Dyspnea at Isotime After 96 Weeks - Double-Blind Phase</title>
          <description>Borg scale assessed degreee of discomfort on a scale from 0 (Nothing at all) to 10 (Maximal)</description>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.16"/>
                    <measurement group_id="O2" value="3.8" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1131</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg Scale of Peak Dyspnea After 96 Weeks - Double-Blind Phase</title>
        <description>Borg scale assessed degreee of discomfort on a scale from 0 (Nothing at all) to 10 (Maximal)</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Borg Scale of Peak Dyspnea After 96 Weeks - Double-Blind Phase</title>
          <description>Borg scale assessed degreee of discomfort on a scale from 0 (Nothing at all) to 10 (Maximal)</description>
          <units>unit on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="0.14"/>
                    <measurement group_id="O2" value="5.6" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9071</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg Scale of Peak Leg Discomfort After 96 Weeks - Double-Blind Phase</title>
        <description>Borg scale assessed degreee of discomfort on a scale from 0 (Nothing at all) to 10 (Maximal)</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Borg Scale of Peak Leg Discomfort After 96 Weeks - Double-Blind Phase</title>
          <description>Borg scale assessed degreee of discomfort on a scale from 0 (Nothing at all) to 10 (Maximal)</description>
          <units>unit on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.18"/>
                    <measurement group_id="O2" value="4.1" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6878</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Evaluation at 8 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Evaluation at 8 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>unit on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.999"/>
                    <measurement group_id="O2" value="0.32" spread="0.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>3.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Evaluation at 16 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Evaluation at 16 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="1.068"/>
                    <measurement group_id="O2" value="0.35" spread="1.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.66</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Evaluation at 32 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 32 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Evaluation at 32 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="1.153"/>
                    <measurement group_id="O2" value="0.30" spread="1.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.91</ci_lower_limit>
            <ci_upper_limit>3.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Evaluation at 48 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Evaluation at 48 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.143"/>
                    <measurement group_id="O2" value="0.25" spread="1.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.97</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Evaluation at 64 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 64 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Evaluation at 64 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.168"/>
                    <measurement group_id="O2" value="0.25" spread="1.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.02</ci_lower_limit>
            <ci_upper_limit>3.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Evaluation at 80 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 80 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Evaluation at 80 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="1.217"/>
                    <measurement group_id="O2" value="0.10" spread="1.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.10</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Evaluation at 96 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Evaluation at 96 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="1.222"/>
                    <measurement group_id="O2" value="0.10" spread="1.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.22</ci_lower_limit>
            <ci_upper_limit>3.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Evaluation at 8 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Evaluation at 8 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="1.134"/>
                    <measurement group_id="O2" value="0.34" spread="1.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>3.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Evaluation at 16 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Evaluation at 16 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="1.206"/>
                    <measurement group_id="O2" value="0.30" spread="1.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.05</ci_lower_limit>
            <ci_upper_limit>3.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Evaluation at 32 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 32 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Evaluation at 32 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="1.281"/>
                    <measurement group_id="O2" value="0.20" spread="1.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.40</ci_lower_limit>
            <ci_upper_limit>3.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Evaluation at 48 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Evaluation at 48 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="1.365"/>
                    <measurement group_id="O2" value="0.18" spread="1.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.61</ci_lower_limit>
            <ci_upper_limit>3.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Evaluation at 64 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 64 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Evaluation at 64 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="1.250"/>
                    <measurement group_id="O2" value="0.16" spread="1.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.53</ci_lower_limit>
            <ci_upper_limit>3.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Evaluation at 80 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 80 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Evaluation at 80 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="1.284"/>
                    <measurement group_id="O2" value="0.09" spread="1.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.36</ci_lower_limit>
            <ci_upper_limit>3.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Evaluation at 96 Weeks - Double-Blind Phase</title>
        <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Evaluation at 96 Weeks - Double-Blind Phase</title>
          <description>The evaluation represented the global opinion of the overall clinical condition on a scale of: 1-2 (Poor), 3-4 (Fair), 5-6 (Good), 7-8 (Excellent)</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="1.455"/>
                    <measurement group_id="O2" value="0.03" spread="1.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.82</ci_lower_limit>
            <ci_upper_limit>3.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire Total Score at 96 Weeks - Double-Blind Phase</title>
        <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire Total Score at 96 Weeks - Double-Blind Phase</title>
          <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="1.13"/>
                    <measurement group_id="O2" value="40.5" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0072</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.97</ci_lower_limit>
            <ci_upper_limit>-1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire Activity Component Score at 96 Weeks - Double-Blind Phase</title>
        <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire Activity Component Score at 96 Weeks - Double-Blind Phase</title>
          <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" spread="1.39"/>
                    <measurement group_id="O2" value="54.6" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2029</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.91</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire Impact Component Score at 96 Weeks - Double-Blind Phase</title>
        <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire Impact Component Score at 96 Weeks - Double-Blind Phase</title>
          <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="1.25"/>
                    <measurement group_id="O2" value="30.4" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0313</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.84</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire Symptoms Component Score at 96 Weeks - Double-Blind Phase</title>
        <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire Symptoms Component Score at 96 Weeks - Double-Blind Phase</title>
          <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4" spread="1.73"/>
                    <measurement group_id="O2" value="45.5" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.37</ci_lower_limit>
            <ci_upper_limit>-4.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With COPD Exacerbation (Survival Analysis) - Double-Blind Phase</title>
        <description>COPD exacerbation is a complex of symptoms related to COPD with a duration of three days or more requiring a change of treatment.</description>
        <time_frame>baseline, 96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With COPD Exacerbation (Survival Analysis) - Double-Blind Phase</title>
          <description>COPD exacerbation is a complex of symptoms related to COPD with a duration of three days or more requiring a change of treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6541</p_value>
            <p_value_desc>Based on a MMRM analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.940</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.719</ci_lower_limit>
            <ci_upper_limit>1.230</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 100 Weeks - Open-Label Phase</title>
        <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
        <time_frame>baseline, 100 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following tiotropium</description>
          </group>
        </group_list>
        <measure>
          <title>90% Constant Work Rate (CWR) Treadmill Endurance Time at 100 Weeks - Open-Label Phase</title>
          <description>Efficacy was assessed by measuring the exercise duration during a treadmill exercise test.</description>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.25" lower_limit="297.63" upper_limit="382.14"/>
                    <measurement group_id="O2" value="358.80" lower_limit="318.05" upper_limit="404.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4443</p_value>
            <p_value_desc>Based on a ANCOVA analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 100 Weeks - Open-Label Phase</title>
        <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
        <time_frame>baseline, 100 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following tiotropium</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Expiratory Volume in 1 Second (FEV1) at 100 Weeks - Open-Label Phase</title>
          <description>FEV1 is the maximal amount of air you can forcefully exhale in one second.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.02"/>
                    <measurement group_id="O2" value="1.23" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8644</p_value>
            <p_value_desc>Based on a ANCOVA analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Forced Vital Capacity (FVC) at 100 Weeks - Open-Label Phase</title>
        <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
        <time_frame>baseline, 100 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following tiotropium</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Forced Vital Capacity (FVC) at 100 Weeks - Open-Label Phase</title>
          <description>FVC is the volume of air that can be forcibly blown out after full inspiration.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="0.05"/>
                    <measurement group_id="O2" value="2.77" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4277</p_value>
            <p_value_desc>Based on a ANCOVA analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire Total Score at 100 Weeks - Open-Label Phase</title>
        <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
        <time_frame>baseline, 100 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following tiotropium</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire Total Score at 100 Weeks - Open-Label Phase</title>
          <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.82" spread="1.28"/>
                    <measurement group_id="O2" value="39.21" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7071</p_value>
            <p_value_desc>Based on a ANCOVA analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.81</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire Activity Component Score at 100 Weeks - Open-Label Phase</title>
        <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
        <time_frame>baseline, 100 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following tiotropium</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire Activity Component Score at 100 Weeks - Open-Label Phase</title>
          <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.57" spread="1.57"/>
                    <measurement group_id="O2" value="54.46" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6556</p_value>
            <p_value_desc>Based on a ANCOVA analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>4.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire Impact Component Score at 100 Weeks - Open-Label Phase</title>
        <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
        <time_frame>baseline, 100 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following tiotropium</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire Impact Component Score at 100 Weeks - Open-Label Phase</title>
          <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.65" spread="1.38"/>
                    <measurement group_id="O2" value="29.67" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9896</p_value>
            <p_value_desc>Based on a ANCOVA analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.44</ci_lower_limit>
            <ci_upper_limit>3.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George's Respiratory Questionnaire Symptoms Component Score at 100 Weeks - Open-Label Phase</title>
        <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
        <time_frame>baseline, 100 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following tiotropium</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George's Respiratory Questionnaire Symptoms Component Score at 100 Weeks - Open-Label Phase</title>
          <description>Score summarises the impact of disease on overall health status with zero indicating best health status and 100 indicating worst possible health status.</description>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.47" spread="1.94"/>
                    <measurement group_id="O2" value="41.14" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0807</p_value>
            <p_value_desc>Based on a ANCOVA analysis with terms for treatment, centre and baseline.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.19</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs and Physical Examination, Including Vital Status</title>
        <description>Clinical Relevant Abnormalities for Vital Signs and Physical examination, including vital status. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events.</description>
        <time_frame>From first drug administration until 30 days after last drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium</title>
            <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following placebo</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium / Open Tiotropium</title>
            <description>Patients receive open label tiotropium following tiotropium</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs and Physical Examination, Including Vital Status</title>
          <description>Clinical Relevant Abnormalities for Vital Signs and Physical examination, including vital status. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="260"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood pressure increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxygen saturation decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 30 days after last drug administration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients randomized to receive treatment with matching placebo</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium</title>
          <description>Patients randomized to treatment with Tiotropium 18 micrograms</description>
        </group>
        <group group_id="E3">
          <title>Placebo / Open Tiotropium</title>
          <description>Patients receive open label tiotropium following placebo</description>
        </group>
        <group group_id="E4">
          <title>Tiotropium / Open Tiotropium</title>
          <description>Patients receive open label tiotropium following tiotropium</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

